Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics Statistics
Share Statistics
Barinthus Biotherapeutics has 40.23M shares outstanding. The number of shares has increased by 2.33% in one year.
| Shares Outstanding | 40.23M |
| Shares Change (YoY) | 2.33% |
| Shares Change (QoQ) | 0.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 36.57M |
| Failed to Deliver (FTD) Shares | 1.38K |
| FTD / Avg. Volume | 4.33% |
Short Selling Information
The latest short interest is 25.37K, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 25.37K |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 0.51 |
Valuation Ratios
The PE ratio is -0.78 and the forward PE ratio is -0.65. Barinthus Biotherapeutics's PEG ratio is 0.04.
| PE Ratio | -0.78 |
| Forward PE | -0.65 |
| PS Ratio | 3.18 |
| Forward PS | 2.7 |
| PB Ratio | 0.37 |
| P/FCF Ratio | -1.6 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Barinthus Biotherapeutics has an Enterprise Value (EV) of 12.53M.
| EV / Earnings | -0.21 |
| EV / Sales | 0.84 |
| EV / EBITDA | -0.23 |
| EV / EBIT | -0.18 |
| EV / FCF | -0.42 |
Financial Position
The company has a current ratio of 8.03, with a Debt / Equity ratio of 0.09.
| Current Ratio | 8.03 |
| Quick Ratio | 8.03 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 8.45 |
| Cash Flow / Debt | -2.41 |
| Interest Coverage | -1282.45 |
Financial Efficiency
Return on equity (ROE) is -0.47% and return on capital (ROIC) is -47.7%.
| Return on Equity (ROE) | -0.47% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -47.7% |
| Revenue Per Employee | $142,561.9 |
| Profits Per Employee | $-581,657.14 |
| Employee Count | 105 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -153K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -55.88% in the last 52 weeks. The beta is -0.8, so Barinthus Biotherapeutics's price volatility has been lower than the market average.
| Beta | -0.8 |
| 52-Week Price Change | -55.88% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.21 |
| Relative Strength Index (RSI) | 53.8 |
| Average Volume (20 Days) | 31.96K |
Income Statement
In the last 12 months, Barinthus Biotherapeutics had revenue of 14.97M and earned -61.07M in profits. Earnings per share was -1.55.
| Revenue | 14.97M |
| Gross Profit | 14.97M |
| Operating Income | -67.97M |
| Net Income | -61.07M |
| EBITDA | -55.37M |
| EBIT | -67.97M |
| Earnings Per Share (EPS) | -1.55 |
Balance Sheet
The company has 110.66M in cash and 12.01M in debt, giving a net cash position of 98.66M.
| Cash & Cash Equivalents | 110.66M |
| Total Debt | 12.01M |
| Net Cash | 98.66M |
| Retained Earnings | -237.66M |
| Total Assets | 160.33M |
| Working Capital | 110.08M |
Cash Flow
In the last 12 months, operating cash flow was -28.94M and capital expenditures -892K, giving a free cash flow of -29.83M.
| Operating Cash Flow | -28.94M |
| Capital Expenditures | -892K |
| Free Cash Flow | -29.83M |
| FCF Per Share | -0.76 |
Margins
Gross margin is 100%, with operating and profit margins of -454.07% and -408%.
| Gross Margin | 100% |
| Operating Margin | -454.07% |
| Pretax Margin | -409.03% |
| Profit Margin | -408% |
| EBITDA Margin | -369.92% |
| EBIT Margin | -454.07% |
| FCF Margin | -199.29% |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -147.62% |
| FCF Yield | -70.61% |
Analyst Forecast
The average price target for BRNS is $3, which is 185.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 185.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -1.62 |
| Piotroski F-Score | 3 |